Multiple formation of chondromas. (Dorland, 27th ed)
| Synonym |
|---|
| Chondromatosis |
| Timeframe | Studies, This Condition (%) | All Conditions % |
|---|---|---|
| pre-1990 | 5 (41.67) | 23.3326 |
| 1990's | 1 (8.33) | 12.5806 |
| 2000's | 2 (16.67) | 18.1394 |
| 2010's | 4 (33.33) | 28.8240 |
| 2020's | 0 (0.00) | 9.53 |
| Drug | Indicated | Relationship Strength | Studies | Trials |
|---|---|---|---|---|
| alpha-hydroxyglutarate | 0 | low | 1 | 0 |
| gallium citrate | 0 | low | 1 | 0 |
| gallium | 0 | low | 1 | 0 |
| small cardioactive peptide a | 0 | low | 1 | 0 |
| gadolinium dtpa | 0 | low | 1 | 0 |
| technetium tc 99m diphosphonate | 0 | low | 1 | 0 |
| technetium tc 99m medronate | 0 | low | 2 | 0 |
| eye | 0 | low | 1 | 0 |
| Protein | Potency Measurements | Inhibition Measurements | Activation Measurements | Drugs |
|---|---|---|---|---|
| Methylcytosine dioxygenase TET2 | 0 | 1 | 1 | 2 |
| Luciferase | 1 | 0 | 0 | 1 |
| hypoxia-inducible factor 1 alpha subunit | 1 | 0 | 0 | 1 |
| progesterone receptor | 1 | 0 | 0 | 1 |
| estrogen-related nuclear receptor alpha | 1 | 0 | 0 | 1 |
| pregnane X nuclear receptor | 1 | 0 | 0 | 1 |
| estrogen nuclear receptor alpha | 1 | 0 | 0 | 1 |
| peroxisome proliferator activated receptor gamma | 1 | 0 | 0 | 1 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | 1 | 0 | 0 | 1 |
| Histone H2A.x | 1 | 0 | 0 | 1 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | 1 | 0 | 0 | 1 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | ||||